Who Owns MiniMed?

Alfred E. Mann, a biomedical entrepreneur who had already founded several medical device companies, established MiniMed in 1983 to commercialize insulin pump therapy. Before the pump, people with insulin-dependent diabetes managed glucose with repeated daily injections and manual blood draws. MiniMed's pumps delivered continuous basal insulin and established the category.

The company grew quickly through the 1990s as pumps gained acceptance in type 1 diabetes care. Sales reached $36 million in 1994, and the company listed on the Nasdaq under ticker MNMD. Revenue hit $294 million by calendar 2000, growing at a 43% annual rate.

Medtronic acquired MiniMed in 2001 and kept the name, the Northridge base, and much of the original team. Under Medtronic the brand hit repeated firsts: the first integrated pump and CGM system in 2006, the first automatic insulin suspend at a preset low threshold in 2009, predictive suspend algorithms in 2015, and the MiniMed 670G in 2017, the world's first hybrid closed-loop system that adjusted basal insulin automatically.

The 780G, rolled out internationally from 2020, added automatic correction boluses and Meal Detection technology that doses for missed or miscounted meal announcements. The InPen smart pen, added through the Companion Medical acquisition in 2020, brought injection users into the ecosystem. Simplera Sync, launched in 2025, gave the brand an all-in-one disposable sensor, and the Abbott-manufactured Instinct sensor followed.

Medtronic announced the diabetes business would separate in May 2025, and the new company reclaimed the MiniMed name that June. The brand's second stint as an independent company began with the March 6, 2026 Nasdaq listing under MMED and became complete with the October 15, 2026 split-off, the largest medtech separation on record.